Latest News

PharmaTech Outlook Selects GenPro to be Among 2017's Top 10 Solution Providers to Biopharma Discovery and Development Organizations


Back

GenPro adds Two Esteemed Scientists to Scientific Advisory Board

April 2, 2017: Two renowned leaders in oncology epigenetics recently joined Genome Profiling’s (GenPro’s) Scientific Advisory Board. Christopher Mason, Ph.D., is Assistant Professor of Integrative Functional Genomics, Clinical Genetics and Synthetic Biology at Weill Cornell Medical College in New York where he is a recognized leader in his field. He is well published and a frequent speaker in the areas of high-throughput sequencing-based methods to generate cell-specific molecular maps of genetic, epigenetic, and transcriptional activity to provide multi-dimensional molecular portraits of development and disease. He and his team are accomplished at developing algorithms to leverage these data for detecting, cataloging and functionally annotating interactions between these molecular changes and also connect them to larger datasets (ENCODE, TCGA, ICGC) for replication and contextualization. His vision is that these systems-based methods will enable such a rich understanding of the functional elements of the human genome that we can begin to repair or re-engineer these genetic networks for attenuating and ameliorating disease.

Ajay Goel, Ph. D. has also joined the GenPro Scientific Advisory Board. Dr. Goel is Professor and Director of Baylor Health's Scott and White Center for Gastrointestinal Research and the Center for Translational Genomics and Oncology. The overarching theme in Dr. Goel's research is to gain insights into the molecular pathogenesis of human gastrointestinal cancers as it relates to cancer prevention. Dr Goel is also well published and a frequent speaker at scientific meetings. He and his team perform basic, translational and clinical studies that involve deciphering the interplay between genetic and epigenetic alterations in gastrointestinal cancers, including colorectal, pancreatic, gastric and hepatocellular disease including the discovery and development of clinically useful biomarkers for the early detection of colorectal polyps and cancers, and other tumors within the gastrointestinal tract (pancreatic, gastric and liver) and to develop prognostic and predictive biomarkers that can help guide therapeutic treatments for patients with colorectal and other gastrointestinal cancers.

Drs. Goel and Mason, join two existing members of GenPro’s Scientific Advisory Board, Dr. James Serum, and Ian Wright. Dr. Serum is formerly vice president of R&D at Agilent Technologies and founder of Agilent's bio-science business, Jim brings 43 years' experience in analytical diagnostics as a scientist, entrepreneur, VC partner, and federal science and technology policy advisor engaged with NAS and NIST. He served on the board of directors of numerous emerging technology companies at various stages of commercial development. Mr. Wright, formerly VP and Head of the Strategic Innovation Group for Siemens Healthcare Diagnostics, is presently CSO of the Advanced Clinical Bio-Systems Institute at Cedars-Sinai Medical Center. His career spans over 30 years in life-science commercialization and technology development.